CA 4948

Drug Profile

CA 4948

Alternative Names: AU 4948; CA-4948

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Curis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Dec 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (PO) (NCT03328078)
  • 09 Dec 2017 Pharmacodynamics and adverse events data from a preclinical study in Haematological malignancies presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)
  • 07 Nov 2017 US FDA approves IND application for CA 4948 in Non-Hodgkin's lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top